Association between apolipoprotein E ε4 and longitudinal cognitive decline: Nested case-control study among chinese community-dwelling elders

Neuropsychobiology

Volumn 64, Issue 2, 2011, Pages 102-109

  Ma, Fei ^a   Wang, Jianhua ^a   Miao, Rujuan ^a   Zhao, Wei ^a   Wang, Qian ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Apolipoprotein E 4; Cognitive decline; Nested case control study

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

AGED; ARTICLE; CASE CONTROL STUDY; CHINESE; COGNITIVE DEFECT; CONTROLLED STUDY; DNA POLYMORPHISM; EDUCATIONAL STATUS; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GROUPS BY AGE; HUMAN; LIPID ANALYSIS; MALE; MEMORY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; COGNITION DISORDERS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GERIATRIC ASSESSMENT; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; RESIDENCE CHARACTERISTICS; RISK FACTORS;

EID: 79959681579     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000324991     Document Type: Article

References (43)

1. Michaelson D: Apolipoprotein E4: the most prevalent yet understudied genetic risk factor of Alzheimer's disease. Alzheimers 2008; 4:149.
2. Ertekin-Taner N: Genetics of Alzheimer's disease: a centennial review. Neurol Clin 2007;25:611-667. (Pubitemid 47058875)
3. Goldbourt U, Schnaider-Beeri M, Davidson M: Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci 2007;257:177-181. (Pubitemid 46856494)
4. Gomez-Tortosa E, Barquero S, Baron M, Ros R, Manzano S, Sainz M, Almaraz C, Gomez-Garre P, Jimenez-Escrig A: Apolipoprotein E genotype and variability in age at onset in sib-pairs with familial Alzheimer's disease. Alzheimers Dementia 2006;2:S189-S190.
5. Roberta Perri, Laura Serra, Giovanni Augusta Carlesimo, Carlo Caltagirone: Amnestic mild cognitive impairment: difference of memory profile in subjects who converted or did not convert to Alzheimer's disease. Neuropsychology 2007;21:549-558. (Pubitemid 47496206)
6. Choi MS, Lee JH: Biopsy-proven young-onset Alzheimer's disease with parkinsonism. Alzheimers Dementia 2006;2:S262.
7. Cho H, Kwan J, Yoon B: The effect of inhibitors of acetylcholinesterase on gait functions in Alzheimer's disease and mild cognitive impairment. Parkinsonism Relat Dis 2008;14:S72.
8. Tupler LA, Krishnan KR, Greenberg DL, Marcovina SM, Payne ME, MacFall JR, Charles HC, Doraiswamy PM: Predicting memory decline in normal elderly: Genetics, MRI, and cognitive reserve. Neurobiol Aging 2007;28:1644-1656. (Pubitemid 47384943)
9. DeCoteau WE, Jurado A, Dudzic E: The relationship between hypertension and Alzheimer's disease. Am J Hypertens 1999;2: 198.
10. Reiss AB, Siller KA, Rahman MM, Chan E, Ghiso J, de Leon M: Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging 2004; 25:977-989. (Pubitemid 38798059)
11. Xu W, Qiu C, Winblad B, Fratiglioni L: Borderline diabetes mellitus and risk of dementia and Alzheimer disease: A population-based longitudinal study. Alzheimers Dementia 2006;2:S153.
12. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thai L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58: 1985-1992. (Pubitemid 33143977)
13. Mungas D, Marshall SC, Weldon M, Haan M, Reed BR: Age and education correction of the Mini-Mental State Examination for English and Spanish speaking elderly. Neurology 1996;46:700-706. (Pubitemid 26099636)
14. Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015-1022. (Pubitemid 20012268)
15. Ng TP, Niti M, Chiam PC, Kua EH: Ethnic and educational differences in cognitive test performance on Mini-Mental State Examination in Asians. Am J Geriatr Psychiatry 2007;15:130-139.
16. Kalmijn S, Feskens EJ, Kromhout D: Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27: 2230-2235. (Pubitemid 26427198)
17. Howieson DB, Holm LA, Kaye JA, Oken BS, Howieson J: Neurologic function in the optimally healthy oldest old: neuropsychological evaluation. Neurology 1993;43:1882-1886. (Pubitemid 23318849)
18. Moss M, Albert MS, Butters N: Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease and alcoholic Korskoff's syndrome. Arch Neurol 1986;43:239-246. (Pubitemid 16117835)
19. Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test and scoring booklet; in Goodglass H, Kaplan E (eds): The Assessment of Aphasia and Related Disorders, ed 2. Philadelphia, Lea & Febiger, 1983.
20. Inouye SK, Albert MS, Mohs R, Sun K, Berkman LF: Cognitive performance in a high functioning community dwelling elderly population. Gerontology 1993;4:M146-M151. (Pubitemid 23199253)
21. Lezak MD: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995.
22. Radioff LS: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1977;1:385-401.
23. Woo J, Ho SC, Chan SG, Sham A, Yuen YK, Masarei JL: Lipid profile in the Chinese old-old: comparison with younger age groups and relationship with some cardiovascular risk factors and presence of diseases. Cardiology 1993;83:407-414. (Pubitemid 24024568)
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
25. Tang MX, Stern Y, Marder K: The APOE-e4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics. JAMA 1998;279:751-755. (Pubitemid 28114999)
26. Ertekin-Taner N: Genetics of Alzheimer's Disease: a centennial review. Neurologic Clin 2007;25:611-667. (Pubitemid 47058875)
27. Albert SM, Gurland B, Maestre G, Jacobs DM, Stern Y, Mayeux R: APOE genotype influences functional status among elderly without dementia. Am J Med Ethics 1995;60: 583-587. (Pubitemid 26002133)
28. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ: The relationship of APOE genotype to cognitive functioning in African American and White community resident elderly. J Am Geriatr Soc 2001;49:1148-1155. (Pubitemid 32900140)
29. Albert MS, Kenneth J, Savage Cary R, Berkman L, Seeman T, Blazer D, Rowe JW: Predictors of cognitive change in older persons: MacArthur Studies of Successful Aging. Psychol Aging 1995;10:294-303.
30. Zannis VI, Breslow JL: Human VLDL apoE isoprotein polymorphism is explained by genetic variation and post-translational modification. Biochemistry 1981;20:1033-1041. (Pubitemid 11097562)
31. Weisgraber KH, Rall SC Jr, Mehley RW: Human E apoprotein heterogeneity: cysteine-arginine interchanges in the amino acid sequence of the apoE isoforms J Biol Chem 1981;256:9077-9083. (Pubitemid 12208303)
32. Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996;19:53-77. (Pubitemid 26080822)
33. Shigeji N, Kaori M, Nobuhiro Y: Apolipoprotein E genotype and Alzheimer's disease. Lancet 1993;42:737.
34. Altstiel LD, Greenberg DA, Marin D: Apolipoprotein E genotype and cognition in the very old. Lancet 1997;349:1451. (Pubitemid 27212201)
35. Blair CK, Folsom AR, Knopman DS: Atherosclerosis Risk in Communities (ARIC) Study Investigators: APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005;64:268-276.
36. Bunce D, Fratiglioni L, Small BJ, Winblad B, Backman L: APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology 2004;63:816-821. (Pubitemid 39297640)
37. Jones S, Laukka EJ, Small BJ, Fratiglioni L, Bäckman L: A preclinical phase in vascular dementia: cognitive impairment three years before diagnosis. Dement Geriatr Cogn Disord 2004;18:233-239. (Pubitemid 39370296)
38. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M: Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry 2001;58:853-858. (Pubitemid 32979303)
39. Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE: The role of APOE-ε4 in longitudinal cognitive decline. Neurology 2003;60: 1077-1081.
40. Kim KW, Youn JC, Jhoo JH, Lee DY, Lee KU, Lee JH, Woo JI: Apolipoprotein E epsilon 4 allele is not associated with the cognitive impairment in community-dwellingnormal elderly individuals. Int J Geriatr Psychiatry 2002;17:635-640. (Pubitemid 34784719)
41. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ: Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia Aging Study. Stroke 2001; 32:2882-2889.
42. Slooter AJ, van Duijn CM, Bots ML, Ott A, Breteler MB, De Voecht J, Wehnert A, de Knijff P, Havekes LM, Grobbee DE, Van Broeckhoven C, Hofman A: Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl 1998;53:17-29. (Pubitemid 28361766)
43. Skoog I, Hesse C, Aevarsson O, Landahl S, Wahlstrom J, Fredman P, Blennow K: A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurosurg Psychiartry 1998;64:37-43. (Pubitemid 28156535)